Skip to main content
Clinical Trials/NL-OMON48704
NL-OMON48704
Recruiting
Phase 4

EvaluaTIoN of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study) - TINCRBEL study

Vasculaire Geneeskunde0 sites30 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
short bowel syndrome
Sponsor
Vasculaire Geneeskunde
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Vasculaire Geneeskunde

Eligibility Criteria

Inclusion Criteria

  • \-Diagnosis of short bowel syndrome (\<170 cm after Treitz ligamentum) or
  • intestinal malabsorption, diagnosed by an endocrinologist in the AMC
  • \- Current use of TPN
  • \- Age 18 years or over\-
  • \- Indication for anticoagulant therapy (DOAC, vitamin K antagonist, heparin)
  • such as stroke prevention in patients with atrial fibrillation, prevention of
  • venous thromboembolic events

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study\- Symptomatic thrombosis at inclusion\- Major
  • bleeding defined according to the International Society on Thrombosis and
  • Haemostasis(11\) in the 6 months prior to start participation\- Contraindication
  • for direct oral anticoagulanto Chronic treatment with NSAID/Cytochrome
  • P450/PgP dependent co\-medicationo Severe renal (eGFR\<15\) or hepatic
  • impairment (Child Pugh score B or C) o Pregnancy or inadequate use of
  • contraception\- Gastrectomy or short bowel syndrome \< 30 cm after Treitz
  • ligamentum\- Medical or psychological condition that would not permit completion
  • of the study or signing of informed consent, including life expectancy less

Outcomes

Primary Outcomes

Not specified

Similar Trials